Cd200ar ligands for cancer immunotherapy
AssigneeRegents of the University of Minnesota
InventorMichael OLIN
Life of this patent
Estimating the term…
Abstract
The present invention in certain embodiments provides a method of inhibiting PD-1 in a cell by administering a CD200 activation receptor ligand (CD200AR-L) to the cell. The present invention in certain embodiments provides a method of enhancing efficacy of a tumor lysate vaccine in a mammal comprising administering a CD200 activation receptor ligand (CD200AR-L) to the mammal prior to the administration of the tumor lysate vaccine.
Claims25
A method of inhibiting PD-1 in a cell comprising or consisting of administering a CD200 activation receptor ligand (CD200AR-L) to the cell.
(canceled)
7-11. (canceled)
A method of enhancing efficacy of a tumor lysate vaccine in a mammal comprising or consisting of administering a CD200 activation receptor ligand (CD200AR-L) to the mammal prior to the administration of the tumor lysate vaccine.
(canceled)
18-21. (canceled)
(canceled)
Dependencies are inferred from the claim text.